A Phase 4 interventional study of Progesterone in Premature Labour, sponsored by Mohamed Sayed Abdelhafez. Completed at 2 sites in Egypt. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2015-01-15.
Sponsored by Mohamed Sayed Abdelhafez · Phase 4, Interventional, and Prevention
To evaluate the value of vaginal progesterone therapy for reduction of preterm labor in asymptomatic twin pregnancies who have sonographic short cervix
Women with twin pregnancy with transvaginal sonographic cervical length of 20-25 mm at 20-24 weeks gestational age without symptoms, signs or other risk factors of preterm labor will be included in the study. All women will be randomly divided into two groups; one group (study group) received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 20-24 weeks gestational age (study group) and the other group received no treatment (control group)
255 studies on the registry are indexed under Obstetric Labor, Premature; 38 are open to participants now.
This study's enrollment of 182 is above the median of 110 across 155 interventional studies indexed under Obstetric Labor, Premature.
Browse Obstetric Labor, Premature studies →Mohamed Sayed Abdelhafez is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Women received vaginal progesterone suppositories
Drug: Progesterone
Women received no treatment
Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
Also known as: Cyclogest
Preterm labor before 34 weeks
Time frame: Up to 34 weeks gestational age
Neonatal respiratory distress syndrome (RDS)
Time frame: At birth
Early neonatal death (END).
Time frame: One month after birth
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mohamed Sayed Abdelhafez